Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

Trial Profile

A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2019

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Leukaemia; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Dec 2018 Results assessing Nivolumab for Relapsed Hematologic Malignancies after alloHCT, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 09 Nov 2018 Planned primary completion date changed from 31 Dec 2018 to 1 Apr 2022.
    • 09 Nov 2018 Status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top